Skip to main content
. 2022 Feb 23;4:100073. doi: 10.1016/j.conx.2022.100073

Fig. 2.

Fig. 2

Cumulative probability of ovulation (progesterone ≥4.7 ng/mL) following subcutaneous administration of 45–300 mg Depo-Provera or 104 mg Depo-subQ in two trials conducted between 2015 and 2018 [10,11]. Shaded regions are 95% confidence bands. Numbers at-risk are below the x-axis. There were no events among subjects who received a single (x1) dose of Depo-subQ.